首页> 外文期刊>The Lancet >Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
【24h】

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

机译:氯沙坦干预终点降低高血压研究中的心血管发病率和死亡率研究(LIFE):针对阿替洛尔的一项随机试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. METHODS: We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. FINDINGS: Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=0.001); and myocardial infarction (non-fatal and fatal) occurred in 198 and 188, respectively (1.07, 0.88-1.31, p=0.491). New-onset diabetes was less frequent with losartan.Interpretation Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated. Losartan seems to confer benefits beyond reduction in blood pressure.
机译:背景:用β受体阻滞剂和利尿剂降低血压是迄今为止预防高血压患者心血管疾病和死亡的最佳记录。左心室肥大(LVH)是心血管疾病和死亡风险的重要独立指标。我们的目标是确定是否选择性阻断血管紧张素II可以改善LVH,而不是降低血压,从而降低心血管疾病的发病率和死亡率。方法:我们对9193名55-80岁的原发性高血压(血压为160-200 / 95-115 mm Hg)和LVH(通过心电图法确定)的参与者进行了一项双掩盖,随机,平行分组的试验。我们为参与者分配了每日至少一次基于氯沙坦或基于阿替洛尔的降压治疗,至少持续4年,直到1040名患者发生原发性心血管事件(死亡,心肌梗塞或中风)。我们使用Cox回归分析来比较治疗方案。结果:氯沙坦和阿替洛尔组的血压分别下降了30.2 / 16.6(SD 18.5 / 10.1)和29.1 / 16.8 mm Hg(19.2 / 10.1)。主要复合终点发生在508氯沙坦(每1000病人-年23.8)和588阿替洛尔患者(每1000病人-年27.9);相对危险度0.87,95%CI 0.77-0.98,p = 0.021)。 204名氯沙坦和234名阿替洛尔患者死于心血管疾病(0.89,0.73-1.07,p = 0.206); 232和309分别患有致命或非致命性中风(0.75,0.63-0.89,p = 0.001);心肌梗塞和非致命性心肌梗死分别发生在198和188(1.07,0.88-1.31,p = 0.491)。氯沙坦不易发生新发糖尿病。解释说,与阿替洛尔相比,氯沙坦能预防更多的心血管疾病和死亡,因此血压降低相似且耐受性更好。氯沙坦似乎可以带来降血压以外的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号